Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04529070 · ClinicalTrials.gov registry record · NA

Nightmare Rescripting and Rehearsal

A NA study, sponsored by David Moss.

Terminated
Registry status
NA
Development phase
68
Enrollment target

NCT04529070: Clinical Trial NA study, sponsored by David Moss.

NCT04529070 is a NA study that was terminated before completion, run by David Moss. The registered enrollment target is 68 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04529070, a NA study, was terminated before completion, sponsored by David Moss.

TERMINATED
Registry status
NA
Development phase
68 participants
Enrollment target

Study Summary

This study aims to test the efficacy of an abbreviated version of Imagery Rehearsal Therapy administered by non-mental health professionals in a Primary Care setting. This treatment, to be called 'Nightmare Rescripting and Rehearsal Therapy' (NRRT) would arm Primary Care medical personnel with a nonpharmacologic, ten minute intervention for treating recurring nightmares. The study will provide sleep hygiene education to both the control and experiment groups, NRRT to the experiment group only, and compare their Nightmare Distress Questionnaire and Nightmare Frequency Tool at two (2), four (4), and six (6) week intervals.

Primary Outcome

13 questions, 0-4. 0 indicates lower level of distress and effects as related to nightmares.

Interventions

  • BEHAVIORAL standard of care
  • BEHAVIORAL Nightmare Rescripting and Rehearsal

Trial Details

FieldValue
Enrollment Target 68 participants
Start Date 2021-01-21
Est. Completion 2025-12-09
Phase NA
David Moss

7 total trials

Why NCT04529070 stopped before completion

NCT04529070 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).

The record links to 0 conditions, and to 2 interventions - of which standard of care is the first listed.

NCT04529070 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04529070 about?

NCT04529070 is a clinical study titled "Nightmare Rescripting and Rehearsal". This study aims to test the efficacy of an abbreviated version of Imagery Rehearsal Therapy administered by non-mental health professionals in a Primary Care setting. This treatment, to be called 'Nightmare Rescripting and Rehearsal Therapy' (NRRT) would arm Primary Care medical personnel with a non...

What is the current status of trial NCT04529070?

This trial is currently terminated. It is a NA study. The enrollment target is 68 participants. The study started on 2021-01-21. Estimated completion is 2025-12-09.

What interventions are being tested in trial NCT04529070?

The interventions under investigation include: standard of care (BEHAVIORAL), Nightmare Rescripting and Rehearsal (BEHAVIORAL).

Who is sponsoring clinical trial NCT04529070?

This trial is sponsored by David Moss, which has 7 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04529070's enrollment target sits among peer trials

68 1133rd of 2000 higher than 862 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02044497 · 68 participants · Phase 4

    Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients

  • NCT03779854 · 68 participants · Phase 2

    Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

  • NCT03821246 · 68 participants · Phase 2

    Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

  • NCT04115514 · 68 participants · Phase 2

    Treatment of ARDS With Instilled T3

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04529070, the US trial registry maintained by the National Library of Medicine. NCT04529070 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.